| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/13/2011 | US20110009331 Protein kinase c peptides for use in withdrawal |
| 01/13/2011 | US20110009330 Medicament for treating parkinson's disease |
| 01/13/2011 | US20110009317 Conjugates of insulin-like growth factor-1 and poly(ethylene glycol) |
| 01/13/2011 | US20110008473 Use of hypericum perforatum extracts in the treatment of neuropathic pain |
| 01/13/2011 | US20110008468 Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders |
| 01/13/2011 | US20110008466 Methods and compositions for altering cell function |
| 01/13/2011 | US20110008455 Crosslinked Protein Nanocrystals, Crosslinked Protein Nanoaggregates and Method of Preparation Thereof |
| 01/13/2011 | US20110008435 Nanoparticulate and Controlled Release Compositions Comprising Aryl-Heterocyclic Compounds |
| 01/13/2011 | US20110008432 Method for Treating a Patient in Need of Aspirin Therapy |
| 01/13/2011 | US20110008431 Therapeutic tablet for postherpetic neuralgia and method of treating postherpetic neuralgia |
| 01/13/2011 | US20110008425 Treatment for Attention-Deficit Hyperactivity Disorder |
| 01/13/2011 | US20110008424 Sustained Release Solid Formulations and Methods of Manufacturing the Same |
| 01/13/2011 | US20110008412 Oral Formulations for 5-HT-Receptor Agonists, Uses and Methods of Treatment Employing The Same |
| 01/13/2011 | US20110008408 Solid dosage form for treating headaches |
| 01/13/2011 | US20110008357 Antibodies that bind il-18 and methods of inhibiting il-18 activity |
| 01/13/2011 | US20110008350 Extracellular targets for alzheimer's disease |
| 01/13/2011 | US20110008341 Polypeptides and methods for making the same |
| 01/13/2011 | US20110008340 Anti-properdin antibodies |
| 01/13/2011 | US20110008339 Monoclonal antibody and use thereof |
| 01/13/2011 | US20110008338 Treatment of Autoimmune Diseases |
| 01/13/2011 | US20110008337 Treatment of Autoimmune Diseases |
| 01/13/2011 | US20110008336 Treatment of Autoimmune Diseases |
| 01/13/2011 | US20110008334 Nogo-a binding with enhanced affinity and pharmaceutical use thereof |
| 01/13/2011 | US20110008324 Antibody Selective for a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor and Uses Thereof |
| 01/13/2011 | US20110008313 tPA MUTANT IN THE TREATMENT OF ACUTE BRAIN INJURY AND NEURODEGENERATIVE DISORDERS |
| 01/13/2011 | US20110008311 Animal Model and Use of 17Beta-Hydroxysteroid Dehydrogenase Type 7 in the Diagnosis of Anencephaly |
| 01/13/2011 | US20110008310 Methods and compositions for mitochondrial replacement therapy |
| 01/13/2011 | US20110008306 Creatine-ligand compounds and methods of use thereof |
| 01/13/2011 | US20110008302 Compositions and methods for immortalizing cells and screening for anti-cancer agents |
| 01/13/2011 | US20110008300 Cryopreservation of Adipose Tissue for the Isolation of Mesenchymal Stem Cells |
| 01/13/2011 | US20110008298 Method of deriving progenitor cell line |
| 01/13/2011 | US20110008296 Muscle-derived cells having differentiation capacities |
| 01/13/2011 | US20110008290 Method for predicting the therapeutic responsiveness of patients to a medical treatment with an interferon |
| 01/13/2011 | US20110008278 Modulators of paraptosis and related methods |
| 01/13/2011 | US20110008267 Pharmaceutical and Cosmeceutical Wash-Off Mousse Shampoo Compositions, Processes for Preparing the Same and Uses Thereof |
| 01/13/2011 | US20110008259 Modulators of cystic fibrosis transmembrane conductance regulator |
| 01/13/2011 | US20110008254 Radiopharmaceutical composition |
| 01/13/2011 | US20110008251 Methods for Generating Stably Linked Complexes Composed of Homodimers, Homotetramers or Dimers of Dimers and Uses |
| 01/13/2011 | US20110008250 Treatment of Autoimmune Diseases |
| 01/13/2011 | US20110005947 Inhibitors of jak |
| 01/13/2011 | DE102009032902A1 Induktion von α-Helix-Konformationen in Proteinen und Peptiden Induction of α-helical conformations in proteins and peptides |
| 01/13/2011 | CA2767711A1 Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis |
| 01/13/2011 | CA2767592A1 Salts of rasagiline and pharmaceutical preparations thereof |
| 01/13/2011 | CA2767298A1 Cyclic triazo sodium channel blockers |
| 01/13/2011 | CA2767296A1 Cyclic triazo sodium channel blockers |
| 01/13/2011 | CA2767112A1 Etomidate analogues that do not inhibit adrenocortical steroid synthesis |
| 01/13/2011 | CA2767079A1 Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors |
| 01/13/2011 | CA2766937A1 Combined preparation for use as a medicament |
| 01/13/2011 | CA2766649A1 Zinc supplementation to increase responsiveness to metalloprotease therapy |
| 01/12/2011 | EP2273268A2 Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
| 01/12/2011 | EP2272959A1 BMP-11 compositions |
| 01/12/2011 | EP2272847A1 Enantiomers and their use as monoamine neurotransmitter re-uptake inhibitors |
| 01/12/2011 | EP2272844A1 Five-membered ring compound |
| 01/12/2011 | EP2272843A1 Quinoline compound |
| 01/12/2011 | EP2272841A1 Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor |
| 01/12/2011 | EP2272835A1 Novel five-membered ring compound |
| 01/12/2011 | EP2272833A1 2-(3-(4-(2-t-Butyl-6-trifluoromethylpyridin-4-yl)piperazin-1-yl)propylmercapto)pyrimidin-4-ol-fumarate |
| 01/12/2011 | EP2272825A2 N-Protected amino hydroxy adamantane carboxylic acid and process for its preparation |
| 01/12/2011 | EP2272537A2 Salts of conjugated psychotropic drugs and processes of preparing same |
| 01/12/2011 | EP2272515A1 Novel uses of sodium 4-phenylbutyrate (4 pba) and the pharmaceutically acceptable salts thereof |
| 01/12/2011 | EP2272514A1 Use of low dose pipamperone and a second active compound in the treatment of neurodegenerative diseases |
| 01/12/2011 | EP2272513A1 Pharmaceutical compositions for treating cancer |
| 01/12/2011 | EP2272512A1 Pharmaceutical compositions for treating cancer |
| 01/12/2011 | EP2271659A1 Compounds for treating pain |
| 01/12/2011 | EP2271658A1 Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives |
| 01/12/2011 | EP2271650A1 Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| 01/12/2011 | EP2271646A1 Apoptosis signal-regulating kinase 1 inhibitors |
| 01/12/2011 | EP2271644A1 Substituted piperidines as therapeutic compounds |
| 01/12/2011 | EP2271640A2 Piperidine derivatives as cgrp receptor antagonists |
| 01/12/2011 | EP2271638A1 Modulators of dopamine neurotransmission |
| 01/12/2011 | EP2271635A1 Modulators of dopamine neurotransmission |
| 01/12/2011 | EP2271634A1 Modulators of dopamine neurotransmission |
| 01/12/2011 | EP2271625A2 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy |
| 01/12/2011 | EP2271622A2 Heteroaryl derivatives as cftr modulators |
| 01/12/2011 | EP2271613A1 Hydroxymethylcyclohexyl amines |
| 01/12/2011 | EP2271612A2 Rasagiline mesylate particles and process for the preparation thereof |
| 01/12/2011 | EP2271405A2 Nip thiazole derivatives as inhibitors of 11-beta-hydorxysteroid dehydrogenase-1 |
| 01/12/2011 | EP2271358A2 Neurodegenerative disorders |
| 01/12/2011 | EP2271344A1 Methods of treating disease-induced ataxia and non-ataxic imbalance |
| 01/12/2011 | EP2271340A2 Pharmaceutical preparation comprising stephaglabrin sulfate for treating demyelinating diseases of the nervous system and for promoting restoration of the myelin sheath of nerve fibers |
| 01/12/2011 | EP2271338A1 Method for treating neurological disorders with imidazolium and imidazolinium compounds |
| 01/12/2011 | EP2271332A1 Use of compounds in the treatment of tau-induced cytotoxicities |
| 01/12/2011 | EP2271312A2 Nerve repair with a hydrogel and optional adhesive |
| 01/12/2011 | EP2271218A1 Use and composition for treating dementia |
| 01/12/2011 | EP2183250B1 Naphthyridine derivatives as potassium channel modulators |
| 01/12/2011 | EP2094677B1 Thiadiazole derivatives for the treatment of neuro-degenerative diseases |
| 01/12/2011 | EP2089368B1 Diaminocyclohexane and diaminocyclopentane derivatives |
| 01/12/2011 | EP2081890B1 Arylsulfonyl pyrrolidines as 5-ht6 inhibitors |
| 01/12/2011 | EP1943242B1 Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists |
| 01/12/2011 | EP1863819B1 Diazabicyclic aryl derivatives and their use as chinolinergic ligands at the nicotinic acetylcholine receptors |
| 01/12/2011 | EP1802616B1 Novel azabicyclic aryl derivatives and their medical use |
| 01/12/2011 | EP1670784B1 Heteroaryl-substituted imdazole derivatives as glutamate receptor antagonists |
| 01/12/2011 | EP1613341B1 Use of slurp-1 for treating diseases related to acetylcholine receptors dysfunction |
| 01/12/2011 | EP1583541B1 Compounds and methods for increasing neurogenesis |
| 01/12/2011 | EP1560580B1 Sulfonamides, sulfamates and sulfamides as gamma-secretase inhibitors |
| 01/12/2011 | EP1517907B1 Azabicyclo-octane and nonane derivatives with ddp-iv inhibiting activity |
| 01/12/2011 | EP1439863B1 Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism |
| 01/12/2011 | EP1402266B1 Reducing RISK OF COMPLICATIONS OF PREMATURITY |
| 01/12/2011 | EP1334103B1 Methods for treatment of disease-induced peripheral neuropathy and related conditions |
| 01/12/2011 | CN1950371B Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands |